Venlafaxine Hydrochloride for the Treatment of Hot Flashes

@article{Schober2003VenlafaxineHF,
  title={Venlafaxine Hydrochloride for the Treatment of Hot Flashes},
  author={Christina E Schober and Nicole T. Ansani},
  journal={Annals of Pharmacotherapy},
  year={2003},
  volume={37},
  pages={1703 - 1707}
}
OBJECTIVE: To review the literature evaluating venlafaxine for the treatment of hot flashes. DATA SOURCES: Clinical literature accessed through MEDLINE (1966–August 2002), PubMed, Harrison's Online, and references of reviewed articles. Key terms used were venlafaxine, Effexor, hot flashes, and vasomotor symptoms. DATA SYNTHESIS: Not all patients experiencing hot flashes are candidates for traditional hormonal therapy. Nonhormonal alternatives have long been explored, but conflicting evidence of… 

Tables from this paper

State of the science: hot flashes and cancer. Part 2: management and future directions.
TLDR
Using existing research to understand, assess, and manage hot flashes in the context of cancer can prevent patient discomfort and improve the delivery of evidence-based care.
Nonestrogen Treatment Modalities for Vasomotor Symptoms Associated with Menopause
TLDR
According to this systematic literature review, postmenopausal vasomotor treatments that have been shown to be safe and effective in short-term use include black cohosh, exercise, gabapentin, medroxyprogesterone acetate, SSRIs (ie, paroxetine hydrochloride), and soy protein.
The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials
TLDR
Most studies have indicated the efficacy and safety of some antidepressants, such as SSRIs and SNRIs, in decreasing the frequency and severity of HF.
Advances in the Treatment of Menopausal Symptoms
TLDR
An evidence-based discussion considering the effectiveness of hormonal and nonhormonal therapies for the relief of vasomotor symptoms and vaginal atrophy is presented.
Dealing with vasomotor symptoms in patients with breast cancer, what options do we have?
  • P. Susana
  • Medicine
    International Journal of Family & Community Medicine
  • 2018
TLDR
The SWAN study (an observational study of the menopause transition), which enrolled 3302 women and had a 17-year follow up, showed an average total mean duration of 7.4 years and a mean persistence after the final menstrual period (FMP), which included young women with a lower educational level, as well as stress, depression and anxiety.
Seizure in venlafaxine overdose: a 10-year retrospective review of the California poison control system
TLDR
Optimal observation time with respect to seizures after overdose of immediate-release formulation of venlafaxine is 18’h (24 h if ingested with other medications), and 21 H for patients who are poisoned with the sustained- release formulation.
Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor
TLDR
DVS is a new 5-HT and NE reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios, suggesting utility in a variety of central nervous system-related disorders.
Treatment of menopausal symptoms post-Women’s Health Initiative: refinement of existing treatments and development of new therapies
TLDR
New formulations of hormone therapy, as well as new treatments, are evolving to aid the reduction of menopausal symptoms and long-term risks of common chronic disease processes that accelerate after the menopause.
...
1
2
...

References

SHOWING 1-10 OF 16 REFERENCES
Venlafaxine for the control of hot flashes: results of a longitudinal continuation study.
TLDR
Evidence is provided that venlafaxine has intermediate term efficacy and good tolerability as a treatment for hot flashes and nurses can inform symptomatic women that an effective nonhormonal alternative exists to control their hot flashes.
Phase III evaluation of fluoxetine for treatment of hot flashes.
  • C. Loprinzi, J. Sloan, T. Rummans
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
This dose of fluoxetine resulted in a modest improvement in hot flashes, and was well tolerated.
Aetiology and Management
TLDR
Evidence-based information is provided about available treatment options for hot flash management, with special consideration of populations such as breast cancer survivors.
Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors.
  • C. Loprinzi, T. Pisansky, E. Perez
  • Medicine, Psychology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
Venlafoxine appears to represent an efficacious new method to alleviate hot flashes in breast cancer survivors and men who undergo androgen-deprivation therapy.
Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.
TLDR
Venlafaxine hydrochloride appears to represent an efficacious new method for alleviating hot flashes in men undergoing androgen ablation therapy and further evaluation of this compound for alleviation hot flashes is indicated.
Menopausal Flushing: Double-blind Trial of a Non-hormonal Medication
TLDR
The relatively mild side effects and the absence of potentially harmful oestrogenic effects suggest that clonidine in the dose range 25 to 75 μg twice daily is a useful addition or alternative to the existing therapy for this common symptom of the menopause.
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.
  • V. Stearns, C. Isaacs, D. Hayes
  • Medicine, Psychology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
TLDR
Paroxetine hydrochloride is a promising new treatment for hot flashes in breast cancer survivors, and warrants further evaluation in a double-blind randomized placebo-controlled trial.
The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives.
  • K. Pritchard
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2001
TLDR
Osteoporosis can be prevented or treated with calcium supplements, exercise, improved diet, bisphosphonates and/or selective estrogen receptor modulators (SERMs) while cardiovascular risk can be reduced by diet and exercise, as well as the appropriate use of lipid lowering and antihypertensive medications.
...
1
2
...